Study of the Effects of Muscular Activity on Iron Metabolism

Study of the Effects of Muscular Activity on Iron Metabolism: A Pilot Study on Healthy Volunteers

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00378469

Enrollment

Registered

2006-09-20

Start date

2006-09-30

Completion date

Unknown

Last updated

2007-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency, Iron Overload

Keywords

Hepcidin, Hemojuvelin, Iron, Healthy volunteers

Brief summary

The aim of this study is to evaluate the effect of muscular exercise on iron metabolism in healthy volunteers. Fourteen healthy male subjects will have to pedal on an ergocycle for 45 minutes, and urine and blood samples will be collected regularly to measure hemojuvelin, hepcidin, iron and transferrin levels.

Detailed description

Hemojuvelin has been described as interfering with hepcidin, a key regulator of iron homeostasis. Hemojuvelin is mainly produced by muscle, and the relationship between exercise and iron metabolism can be questioned about. The aim of this study is to evaluate the effect of muscular exercise on iron metabolism in healthy volunteers. Fourteen healthy male subjects will be investigated at two periods according to a cross-over design after: 1. 45 minutes of exercise on the ergocycle; and 2. no physical exercise. Urine and blood samples will be collected at both periods regularly to measure hemojuvelin, hepcidin, iron and transferrin levels.

Interventions

BEHAVIORAL45 minute exercise on ergocycle

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Male individuals aged between 18 and 40 years old * Body mass index (BMI) between 18 and 25 * Normal at clinical examination * Normal biological variables * Written informed consent

Exclusion criteria

* Mutation C282Y of the HFE gene * Iron metabolism abnormality * Inflammatory syndrome * Chronic pathology or ongoing treatment * Tobacco smoking, alcohol consuming more than 30g/day * History of transfusion or blood-giving within 3 months * Positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of urinary hepcidin	—
Pharmacokinetics of blood hemojuvelin	—

Secondary

Measure	Time frame
Pharmacokinetics of urine and blood iron, transferrin, interleukin-6 (IL-6) and ferritin	—

Countries

France

Contacts

Primary ContactPierre Brissot, MD

pierre.brissot@univ-rennes1.fr33-2-9928-4297

Backup ContactFabrice Lainé, MD

fabrice.laine@chu-rennes.fr33-2-9928-3715

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026